R-verapamil - AGI Therapeutics

Drug Profile

R-verapamil - AGI Therapeutics

Alternative Names: AGI-003; Arverapamil - AGI Therapeutics; Rezular

Latest Information Update: 30 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AGI Therapeutics
  • Class Antiarrhythmics; Antihypertensives; Antineoplastics; Irritable bowel syndrome therapies; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Melatonin receptor modulators; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 22 Sep 2009 Final adverse events data from a Phase-III trial, ARDIS-1, in Diarrhoea-predominant irritable bowel syndrome released by AGI Therapeutics
  • 15 May 2009 Discontinued - Phase-III for Irritable bowel syndrome in European Union (PO)
  • 15 May 2009 Discontinued - Phase-III for Irritable bowel syndrome in South America (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top